Meeting
2015 ASCO Annual Meeting
Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.
Authors
Michael B. Atkins
Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC
Michael B. Atkins , Toni K. Choueiri , F. Stephen Hodi , John A. Thompson , Wen-Jen Hwu , David F. McDermott , Melissa Brookes , Alessandra Tosolini , Scot Ebbinghaus , Zijiang Yang , Christine K. Gause , Rodolfo F. Perini , Antoni Ribas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT02089685
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3009)
DOI
10.1200/jco.2015.33.15_suppl.3009
Abstract #
3009
Poster Bd #
335
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
First Author: Lauren Julia Brown
Poster
2019 ASCO Annual Meeting
Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.
First Author: Georgina V. Long
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.
First Author: Karim Welaya
Poster
2016 ASCO Annual Meeting
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.
First Author: Adil Daud